Text Size

Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00852813
First received: February 26, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

The purpose of the study is to evaluate the tolerance of a higher dose of arabinoxylan-oligosaccharides (AXOS) and their prebiotic activity in healthy subjects.


Condition Intervention Phase
Healthy
 Dietary Supplement: arabinoxylan-oligosaccharides (AXOS)
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2007
Study Completion Date: June 2008
Intervention Details:
    Dietary Supplement: arabinoxylan-oligosaccharides (AXOS)
    intake period: 3 weeks, 10 g/day
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00852813

Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Publications:

Responsible Party: Kristin verbeke, Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier: NCT00852813     History of Changes
Other Study ID Numbers: AXOS 002
Study First Received: February 26, 2009
Last Updated: February 26, 2009
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Katholieke Universiteit Leuven:
tolerance
prebiotic
gastrointestinal effects

ClinicalTrials.gov processed this record on June 18, 2013